NCT05708560 (MAFLD-HBV 1) is a clinical trial in Hepatitis B, Chronic, sponsored by Erasmus Medical Center.

Who is sponsoring NCT05708560?

NCT05708560 is sponsored by Erasmus Medical Center.

What condition does NCT05708560 study?

NCT05708560 studies Hepatitis B, Chronic.

Is NCT05708560 still recruiting?

NCT05708560 is currently status unknown. Last updated 1 February 2023.

Last reviewed 2023-02-01 · How we verify

NCT05708560: MAFLD-HBV 1

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Relationship Between MAFLD and Liver Fibrosis Progression in Patients With Chronic Hepatitis B: a Multicenter Retrospective Cohort Study

Status unknown Last updated 1 February 2023

What this trial tests

trial in Hepatitis B, Chronic in 800 participants. Status unknown.

Timeline

1 March 2022

Primary endpoint
31 January 2023

31 January 2023

Quick facts

Lead sponsor	Erasmus Medical Center
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	800
Start date	1 March 2022
Primary completion	31 January 2023
Estimated completion	31 January 2023
Sites	3 locations across Netherlands

Conditions studied

Hepatitis B, Chronic — all drugs for Hepatitis B, Chronic →

Sponsor

Erasmus Medical Center

Who can join

18 and older, any sex, with Hepatitis B, Chronic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This multicenter retrospective study aims to study the association between the presence of MAFLD and change in liver stiffness over time in untreated and treated patients with chronic hepatitis B

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Hepatitis B, Chronic

Currently open trials in the same condition.

NCT07370207 — Phase 2 Study of AHB-137 in HBeAg Negative Chronic Hepatitis B (CHB) Participants in Asia Pacific Region · Phase 2 · recruiting
NCT06550622 — Improved Sensitivity Detection of Serum HBsAg and HBsAg Reversion · recruiting
NCT06550128 — Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB). · Phase 2 · active not recruiting
NCT06525909 — A Real-world Study of Staging and Grading of Clinical Immune Status in Chronic Hepatitis B · recruiting
NCT05937178 — Real-world Study Optimizing Nucleotide-analogues · recruiting

Other Erasmus Medical Center trials

Trials by the same sponsor.

NCT07406269 — Clinical Evaluation of AI Decision Support for Early Rehabilitation After Surgery · NA · not yet recruiting
NCT07402109 — CBCT Guided Markerless SBRT for Renal Cell Cancer · NA · recruiting
NCT07383194 — Prediction Models for LDLT Outcomes · not yet recruiting
NCT07426575 — Evaluating the Usability of New Dialysis Bags · not yet recruiting
NCT07329296 — The Regenerative Capacity of the Donor Liver After Living Donor Liver Transplantation: an Ambidirectional Cohort Study · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05708560 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Erasmus Medical Center
Last refreshed: 1 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05708560.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing